Taisho Makes Tender Offer For Biofermin In Proposed Japanese Merger
This article was originally published in PharmAsia News
Japan's Taisho Pharmaceutical made a tender offer to acquire Biofermin Pharmaceutical for an amount that could reach $251.4 million. The Taisho offer is for up to 62 percent of Biofermin's outstanding shares. Taisho plans to turn Biofermin, which sells both prescription and over-the-counter drugs, into a subsidiary as part of an effort to strengthen the buyer's development of drugs and food products. Biofermin and its largest shareholder approve of the takeover. (Click here for more - a subscription may be required
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.